Failure of combination therapy with daptomycin and synergistic ceftriaxone for enterococcal endocarditis.

Department of Pharmacy, Island Health, 1952 Bay St, Victoria, BC V8R 1J8, Canada; Department of Laboratory Medicine, Medical Microbiology Division, Island Health, 1952 Bay St, Victoria, BC V8R 1J8, Canada; Department of Pathology and Laboratory Medicine, University of British Columbia, G227–2211 Wesbrook Mall, Vancouver, BC V6T 2B5, Canada; Department of Infectious Diseases, Island Health, 1952 Bay St, Victoria, BC V8R 1J8, Canada

[1]  M. Rybak,et al.  Evaluation of the novel combination of daptomycin plus ceftriaxone against vancomycin-resistant enterococci in an in vitro pharmacokinetic/pharmacodynamic simulated endocardial vegetation model. , 2014, The Journal of antimicrobial chemotherapy.

[2]  J. Pogliano,et al.  Defining Daptomycin Resistance Prevention Exposures in Vancomycin-Resistant Enterococcus faecium and E. faecalis , 2014, Antimicrobial Agents and Chemotherapy.

[3]  S. Miyakis,et al.  Systematic Review and Meta-Analysis of Linezolid versus Daptomycin for Treatment of Vancomycin-Resistant Enterococcal Bacteremia , 2013, Antimicrobial Agents and Chemotherapy.

[4]  L. Miller,et al.  Systematic Review and Meta-Analysis of Linezolid and Daptomycin for Treatment of Vancomycin-Resistant Enterococcal Bloodstream Infections , 2013, Antimicrobial Agents and Chemotherapy.

[5]  V. Nizet,et al.  Treatment of High-Level Gentamicin-Resistant Enterococcus faecalis Endocarditis with Daptomycin plus Ceftaroline , 2013, Antimicrobial Agents and Chemotherapy.

[6]  P. Dohmen,et al.  Daptomycin for the treatment of infective endocarditis: results from a European registry. , 2013, The Journal of antimicrobial chemotherapy.

[7]  C. Arias,et al.  Enterococcal Endocarditis: Can We Win the War? , 2012, Current Infectious Disease Reports.

[8]  C. Arias,et al.  Evaluation of Standard- and High-Dose Daptomycin versus Linezolid against Vancomycin-Resistant Enterococcus Isolates in an In Vitro Pharmacokinetic/Pharmacodynamic Model with Simulated Endocardial Vegetations , 2012, Antimicrobial Agents and Chemotherapy.

[9]  T. Cai,et al.  Comment on: A potential role for daptomycin in enterococcal infections: what is the evidence? , 2011, The Journal of antimicrobial chemotherapy.

[10]  R. Cantón,et al.  A potential role for daptomycin in enterococcal infections: what is the evidence? , 2010, The Journal of antimicrobial chemotherapy.

[11]  Andrew Wang,et al.  Clinical presentation, etiology, and outcome of infective endocarditis in the 21st century: the International Collaboration on Endocarditis-Prospective Cohort Study. , 2009, Archives of internal medicine.

[12]  Michael S. Finney,et al.  Daptomycin for the Treatment of Gram‐Positive Bacteremia and Infective Endocarditis: A Retrospective Case Series of 31 Patients , 2006, Pharmacotherapy.

[13]  D. Snydman,et al.  Evaluation of In Vitro Interaction of Daptomycin with Gentamicin or Beta-lactam Antibiotics Against taphylococcus aureus and Enterococci by FIC Index and Timed-Kill Curves , 2005, Journal of chemotherapy.

[14]  K. Rand,et al.  Daptomycin synergy with rifampicin and ampicillin against vancomycin-resistant enterococci. , 2004, The Journal of antimicrobial chemotherapy.

[15]  M. Rybak,et al.  Daptomycin against multiple drug-resistant staphylococcus and enterococcus isolates in an in vitro pharmacodynamic model with simulated endocardial vegetations. , 2003, Diagnostic microbiology and infectious disease.

[16]  M. Rybak,et al.  Daptomycin Dose-Effect Relationship against Resistant Gram-Positive Organisms , 2003, Antimicrobial Agents and Chemotherapy.